Magazzini, Laura and Pammolli, Fabio and Riccaboni, Massimo (2004): Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure. Published in: The European Journal of Health Economics , Vol. 5, No. 2 (May 2004): pp. 175-182.
Download (394kB) | Preview
This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries. We focus on the competition at the level of single chemical entities, distinguishing between original brands and generic products. Quarterly data, spanning from July 1987 to December 1998, on sales of pharmaceutical products in four countries (USA, UK, Germany, and France) constitute the basis of our analysis. All the products containing major molecules whose patent expiration date lies between 1986 and 1996 are included in our sample. We show how diffusion of generics is linked to the characteristics of the market and investigate how price dynamics of original products are affected by generic competition. Our empirical investigation shows that the dynamics of drug prices and the competition by generic drugs vary significantly across countries. This heterogeneity notwithstanding, a clear distinction seems to emerge. On the one hand, systems that rely on market-based competition in pharmaceuticals promote a clear distinction between firms that act as innovators and firms that act as imitators after patent expiry. Here, original products enjoy premium prices and exclusivity profits under patent protection, and face fierce price competition after patent expiry. On the other hand, in systems that rely on administered prices, penetration by generic drugs tends to be rather limited. Its descriptive and preliminary nature notwithstanding, our analysis seems to have relevant implications at different levels of generality, especially for Europe.
|Item Type:||MPRA Paper|
|Original Title:||Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure|
|Keywords:||Pharmaceuticals; Patent expiration; Off-patent competition|
|Subjects:||L - Industrial Organization > L6 - Industry Studies: Manufacturing > L65 - Chemicals ; Rubber ; Drugs ; Biotechnology
I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets
L - Industrial Organization > L1 - Market Structure, Firm Strategy, and Market Performance > L11 - Production, Pricing, and Market Structure ; Size Distribution of Firms
O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O34 - Intellectual Property and Intellectual Capital
I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health
L - Industrial Organization > L5 - Regulation and Industrial Policy > L52 - Industrial Policy ; Sectoral Planning Methods
D - Microeconomics > D4 - Market Structure, Pricing, and Design > D43 - Oligopoly and Other Forms of Market Imperfection
|Date Deposited:||30. Jun 2009 08:54|
|Last Modified:||08. Jan 2014 00:30|
Ahn S, 2002: “Competition, Innovation, and Productivity Growth: a Review of Theory and Evidence”. OECD Economics Department Working Paper, 317
Ashiya M, 2000: “Weak Entrants are Welcome”. International Journal of Industrial Organization, 18, 975-984.
Bae JP 1997: “Drug Patent Expirations and the Speed of Generic Entry”. HSR: Health Services Research, 32:1, 87-101
Blundell R, Griffith R, Van Reenen J 1995: “Dynamic Count Data Models of Technological Innovation”. The Economic Journal, 105, 429, 333-344
Caves RE, Whinston MD, Hurwitz MA 1991: “Patent expiration, entry and competition in the US pharmaceutical industry”. Brookings Papers on Economic Activity. Microeconomics, 1- 48
Ching ATT 2000: “Dynamic Equilibrium in the Prescription Drug Market after Patent Expiration”. PhD Dissertation, University of Minnesota.
Cohen W, Levin R 1989: “Empirical Studies of Innovation and Market Structure”. In R Schmalensee and J Willing (eds), The Handbook of Industrial Organization, I, Amsterdam: North Holland
Danzon PM, Chao LW 2000: “Cross-national Price Differences for Pharmaceuticals: How Large and Why?” Journal of Health Economics, 19, 159-195
Eswaran M 1994: “Licensees as Entry Barriers”. The Canadian Journal of Economics, 27, 3, 673-688
Gambardella A, Orsenigo L, Pammolli F 2001: “Global competitiveness in pharmaceuticals. A European perspective”. Directorate General Enterprise, European Commission, Brussels
Garattini L, Tediosi F 2000: “A Comparative Analysis of Generics Markets in Five European Countries”. Health Policy, 51, 149-162
Grabowski HG, Vernon JM 1992: “Brand Loyalty, Entry and Price Competition in the Pharmaceuticals after the 1984 Drug Act”. Journal of Law and Economics, 35, 331-350
Grabowski HG, Vernon JM 1996: “Longer patents for increased generic competition in the US”. PharmacoEconomics, 10, 110-123
Hollis A 2000: “The Effect of Brand-Controlled “Pseudo-Generics” on the Canadian Pharmaceutical Market”. Department of Economics, University of Calgary
Hudson J 2000: “Generic Take-Up in the Pharmaceutical Market Following Patent Expiry. A Multi-Country Study”. International Review of Law and Economics, 20, 205-221
Hurwitz MA, Caves RE 1988: “Persuasion or Information?: Promotion and the Shares of Brand Name and Generic Pharmaceuticals”. Journal of Law and Economics, 31, 299-320
Jacobzone S 2000: “Pharmaceutical Policies in OECD countries: reconciling social and industrial goals”. OECD Labor Market and Social Policy Occasional Papers, 40
López-Casanovas G, Jönsson B, eds., 2001: “Reference Pricing and Pharmaceutical Policy: Perspectives on Economics and Innovation”. Kluwer, Dordrecht
Magazzini L, Orsenigo L, Pammolli F 2002: “The intensity of competition after patent expiry in pharmaceuticals: a cross-country analysis”. Revue d’Economie Industrielle, 99.
Mossialos E 1997: “Citizens’ View on Health Systems in the 15 Member States of the European Union”. Health Economics, 6, 109-116
NERA 1998: “Policy relating to generic medicines in the OECD”. Report for the European Commission, Brussels
Scott Morton FM 1997: “Entry Decision in the Generic Pharmaceutical Industry”. NBER Working Paper: 6190
Suh DC 1993: “Effect of Multiple Source Entry on Price Competition After Patent Expiration in the Pharmaceutical Industry”. PhD Dissertation, University of Minnesota
Yi S 1999: “Entry, Licensing and Research Joint Ventures”. International Journal of Industrial Organization, 17, 1-24